Table 5:

Factors associated with residual breast tumor and pathologic complete response (pCR) in univariate analysis.

		ypT0-is		ypT≥1		Chi-2
		Nb	%	Nb	%	p-value
All patients		664	40.8	965	59.2
Period	P1	112	16.9	168	17.4	0.073
	P2	186	28	317	32.8
	P3	366	55.1	480	49.7
Subtypes	Luminal A	56	8.4	337	34.9	<0.0001
	Luminal B Her2−	57	8.6	141	14.6
	Luminal B Her2+	148	22.3	154	16
	Her2+	149	22.4	71	7.4
	Triple Negative	252	38	261	27
	Luminal Her2− Grade?	2	0.3	1	0.1
cT stage	cT0-1	109	16.4	131	13.6	0.087
	cT2	390	58.7	545	56.5
	cT3	130	19.6	220	22.8
	cT4	35	5.3	69	7.2
cN stage	cN0	322	48.5	468	48.5	1
	cN1	333	50.2	484	50.2
	cNx	9	1.4	13	1.3
	Luminal A Grade 1	2	3.6	69	20.5	0.001
	Luminal A Grade 2	54	96.4	268	79.5
		pCR		no pCR		Chi-2
		Nb	%	Nb	%	p-value
All patients		561	34.4	1068	65.6
Period	P1	94	16.8	186	17.4	0.011
	P2	149	26.6	354	33.1
	P3	318	56.7	528	49.4
Subtypes	Luminal A	30	5.3	363	34	<0.0001
	Luminal B Her2−	41	7.3	157	14.7
	Luminal B Her2+	128	22.8	174	16.3
	Her2+	138	24.6	82	7.7
	Triple Negative	223	39.8	290	27.2
	Luminal Her2− Grade?	1	0.2	2	0.2
cT stage	cT0-1	89	15.9	151	14.1	0.045
	cT2	340	60.6	595	55.7
	cT3	102	18.2	248	23.2
	cT4	30	5.3	74	6.9
cN stage	cN0	311	55.4	479	44.9	<0.0001
	cN1	243	43.3	574	53.7
	cNx	7	1.2	15	1.4
	Luminal A Grade 1	2	6.7	69	19	0.065
	Luminal A Grade 2	28	93.3	294	81

Abbreviations: ypT, pathologic tumor status after NAC; cT, clinical tumor size stage; cN, clinical lymph node status.